Literature DB >> 10507277

Compliance and the rehabilitation alliance.

R Aquila1, P J Weiden, M Emanuel.   

Abstract

Expectations for the treatment of schizophrenia have historically been modest, with emphasis on eliminating positive symptoms and keeping patients out of the hospital. Noncompliance with traditional antipsychotic agents, which have limited efficacy and are associated with numerous adverse side effects, has contributed to these low expectations. The atypical antipsychotics can improve compliance because of their better safety, efficacy, and tolerability and thus help raise treatment expectations from mere removal of symptoms to fuller rehabilitation. This rehabilitation can even include the reintegration of patients with schizophrenia into the community. Compliance with any drug regimen, however, does not in itself guarantee the return to a normal life for patients with schizophrenia. Instead, compliance must occur within a rehabilitation alliance--a supportive network that includes the patient, the treating physician, family members and friends, and other caregivers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10507277

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  8 in total

1.  Measuring strategies used by mental health providers to encourage medication adherence.

Authors:  Beth Angell
Journal:  J Behav Health Serv Res       Date:  2006-01       Impact factor: 1.505

2.  Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review.

Authors:  Prakash S Masand; Miquel Roca; Martin S Turner; John M Kane
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

3.  Does assertive community treatment increase medication adherence for people with co-occurring psychotic and substance use disorders?

Authors:  Jennifer I Manuel; Nancy H Covell; Carlos T Jackson; Susan M Essock
Journal:  J Am Psychiatr Nurses Assoc       Date:  2011 Jan-Feb       Impact factor: 2.385

4.  High level of expressed emotions in the family of people with schizophrenia: has a covert abrasive behaviours component been overlooked?

Authors:  Siu-Man Ng; Melody Hiu-Ying Fung; Siyu Gao
Journal:  Heliyon       Date:  2020-11-07

5.  Impact of depression and social support on nonadherence to antipsychotic drugs in persons with schizophrenia in Thailand.

Authors:  Sirijit Suttajit; Sutrak Pilakanta
Journal:  Patient Prefer Adherence       Date:  2010-10-05       Impact factor: 2.711

Review 6.  Improving treatment adherence in your patients with schizophrenia: the STAY initiative.

Authors:  Fernando Cañas; Koksal Alptekin; Jean Michel Azorin; Vincent Dubois; Robin Emsley; Antonio G García; Philip Gorwood; Peter M Haddad; Dieter Naber; José M Olivares; Georgios Papageorgiou; Miquel Roca
Journal:  Clin Drug Investig       Date:  2013-02       Impact factor: 2.859

7.  Factors that influence the prescription of antipsychotics for patients with schizophrenia in china.

Authors:  Tian-Mei Si; Liang Shu; Ke-Qing Li; Xie-He Liu; Qi-Yi Mei; Gao-Hua Wang; Pei-Shen Bai; Li-Ping Ji; Xian-Sheng Chen; Cui Ma; Jian-Guo Shi; Hong-Yan Zhang; Hong Ma; Xin Yu
Journal:  Clin Psychopharmacol Neurosci       Date:  2011-12-31       Impact factor: 2.582

8.  A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia.

Authors:  Haya Ascher-Svanum; Baojin Zhu; Douglas Faries; Frank R Ernst
Journal:  Ann Gen Hosp Psychiatry       Date:  2004-06-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.